According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

When you start Dupixent treatment, you and your doctor will discuss which form (pen or syringe) is right for your (or your child’s) situation. This article describes how the Dupixent pen and ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic ... CSU is a severe form of hives that affects around 1% of the global population, causing ...

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... The drug has got off to a flying start in the US market, achieving rapid uptake since its launch in April, despite ...

Dupixent (dupilumab) is now used to treat over a million patients globally. The recent approval and launch in chronic obstructive pulmonary disease (COPD) have had a successful start, with ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...